国家癌症研究所“癌症登月生物库”
癌症登月生物样本库研究方案
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
研究概览
地位
条件
- 恶性实体肿瘤
- 黑色素瘤
- 急性髓性白血病
- 多发性骨髓瘤
- 解剖学 III 期乳腺癌 AJCC v8
- 解剖学 IV 期乳腺癌 AJCC v8
- 输卵管癌
- 胃癌
- 肺非小细胞癌
- III 期肺癌 AJCC v8
- IV 期肺癌 AJCC v8
- 转移性前列腺癌
- 卵巢癌
- 食道癌
- 浸润性乳腺癌
- IVB 期前列腺癌 AJCC v8
- 临床 IV 期胃癌 AJCC v8
- 临床 IV 期胃食管结合部腺癌 AJCC v8
- 三阴性乳腺癌
- IV 期结直肠癌 AJCC v8
- 原发性腹膜癌
- 临床 IV 期食管腺癌 AJCC v8
- 卵巢高级别浆液性腺癌
- III 期输卵管癌 AJCC v8
- III 期卵巢癌 AJCC v8
- IV 期输卵管癌 AJCC v8
- IV 期卵巢癌 AJCC v8
- 激素受体阳性乳腺癌
- 肺小细胞癌
详细说明
PRIMARY OBJECTIVE:
I. To support current and future investigations into drug resistance and sensitivity and other National Cancer Institute (NCI)-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCI Community Oncology Research Program (NCORP) sites and other National Clinical Trials Network (NCTN) sites.
SECONDARY OBJECTIVES:
I. To provide a service of value to study participants and their medical providers through the performance of molecular profiling assays on tumor samples in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory and reporting of results to physicians and patients that they may opt to use in clinical management, including analysis of data for acquired resistance mechanisms.
II. To enable the development of patient-derived models such as cell lines and xenografts for cancer researchers through the provision of biospecimens from up to 20% of study participants to the NCI's Patient Derived Models Repository (PDMR), a national resource available to investigators.
III. To develop and implement robust approaches in patient and provider engagement to improve understanding of biobanking and its relationship to cancer research and increase representation of minority and underserved study participants in cancer research.
IV. To develop increased capabilities in United States (U.S.) community hospitals and clinics for contribution to cancer research through biobanking activities.
V. To enable secondary research generated from the project through deposition of data in public repositories such as Cancer Research Data Commons (CRDC), The Cancer Imaging Archive (TCIA) and database of Genotypes and Phenotypes (dbGaP) and other potential NCI databases, including clinical, radiology and pathology data with an emphasis on treatment response and outcome data.
VI. To provide residual biospecimens and associated data from the project to the cancer research community.
OUTLINE:
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo computed tomography (CT), positron emission tomography (PET)/CT and/or magnetic resonance imaging (MRI) throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.
研究类型
注册 (估计的)
联系人和位置
学习地点
-
-
-
San Juan、波多黎各、00917
- San Juan Community Oncology Group
-
San Juan、波多黎各、00927
- Centro Comprensivo de Cancer de UPR
-
San Juan、波多黎各、00936
- San Juan City Hospital
-
-
-
-
Alabama
-
Daphne、Alabama、美国、36526
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope、Alabama、美国、36532
- Thomas Hospital
-
Mobile、Alabama、美国、36607
- Mobile Infirmary Medical Center
-
Saraland、Alabama、美国、36571
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Kingman、Arizona、美国、86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Fort Smith、Arkansas、美国、72903
- Mercy Hospital Fort Smith
-
-
California
-
Arroyo Grande、California、美国、93420
- PCR Oncology
-
Bakersfield、California、美国、93301
- AIS Cancer Center at San Joaquin Community Hospital
-
Loma Linda、California、美国、92357
- Veterans Affairs Loma Linda Healthcare System
-
Salinas、California、美国、93901
- Salinas Valley Memorial
-
-
Colorado
-
Brighton、Colorado、美国、80601
- Intermountain Health Platte Valley Hospital
-
Denver、Colorado、美国、80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Golden、Colorado、美国、80401
- Lutheran Hospital - Cancer Centers of Colorado
-
Grand Junction、Colorado、美国、81501
- Saint Mary's Hospital and Regional Medical Center
-
Lafayette、Colorado、美国、80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
-
Connecticut
-
Hartford、Connecticut、美国、06102
- Hartford Hospital
-
-
Delaware
-
Dover、Delaware、美国、19901
- Bayhealth Hospital Kent Campus
-
Milford、Delaware、美国、19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Boca Raton、Florida、美国、33486
- Boca Raton Regional Hospital
-
Deerfield Beach、Florida、美国、33064
- Broward Health North
-
Fort Lauderdale、Florida、美国、33316
- Broward Health Medical Center
-
Tampa、Florida、美国、33606
- Tampa General Hospital
-
-
Georgia
-
Atlanta、Georgia、美国、30342
- Northside Hospital
-
Savannah、Georgia、美国、31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Illinois
-
Bloomington、Illinois、美国、61704
- Illinois CancerCare-Bloomington
-
Chicago、Illinois、美国、60612
- John H Stroger Jr Hospital of Cook County
-
Chicago、Illinois、美国、60625
- Swedish Covenant Hospital
-
Danville、Illinois、美国、61832
- Carle at The Riverfront
-
Decatur、Illinois、美国、62526
- Decatur Memorial Hospital
-
Decatur、Illinois、美国、62526
- Cancer Care Specialists of Illinois - Decatur
-
Evanston、Illinois、美国、60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg、Illinois、美国、61401
- Illinois CancerCare-Galesburg
-
Glenview、Illinois、美国、60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park、Illinois、美国、60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon、Illinois、美国、61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon、Illinois、美国、62864
- SSM Health Good Samaritan
-
Pekin、Illinois、美国、61554
- Illinois CancerCare-Pekin
-
Peoria、Illinois、美国、61615
- Illinois CancerCare-Peoria
-
Urbana、Illinois、美国、61801
- Carle Cancer Center
-
Washington、Illinois、美国、61571
- Illinois CancerCare - Washington
-
-
Iowa
-
Ames、Iowa、美国、50010
- McFarland Clinic - Ames
-
Bettendorf、Iowa、美国、52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Cedar Rapids、Iowa、美国、52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids、Iowa、美国、52402
- Physicians' Clinic of Iowa PC
-
Des Moines、Iowa、美国、50309
- Iowa Methodist Medical Center
-
Des Moines、Iowa、美国、50309
- Blank Children's Hospital
-
Des Moines、Iowa、美国、50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Iowa City、Iowa、美国、52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70808
- Our Lady of the Lake Physician Group
-
New Orleans、Louisiana、美国、70118
- Children's Hospital New Orleans
-
New Orleans、Louisiana、美国、70112
- University Medical Center New Orleans
-
Shreveport、Louisiana、美国、71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta、Maine、美国、04330
- Harold Alfond Center for Cancer Care
-
Belfast、Maine、美国、04915
- MaineHealth Waldo Hospital
-
Biddeford、Maine、美国、04005
- MaineHealth Maine Medical Center - Biddeford
-
Brunswick、Maine、美国、04011
- MaineHealth Cancer Care and IV Therapy - Brunswick
-
Brunswick、Maine、美国、04011
- Mid Coast Hospital
-
Damariscotta、Maine、美国、04543
- MaineHealth LincolnHealth Hospital
-
Farmington、Maine、美国、04938
- MaineHealth Franklin Hospital
-
Lewiston、Maine、美国、04240
- Saint Mary's Regional Medical Center
-
Norway、Maine、美国、04268
- MaineHealth Stephens Hospital
-
Portland、Maine、美国、04102
- Maine Medical Partners Surgical Care
-
Portland、Maine、美国、04102
- MMP Surgical Care Casco Bay
-
Portland、Maine、美国、04102
- MaineHealth Maine Medical Center - Portland
-
Rockport、Maine、美国、04856
- Penobscot Bay Medical Center
-
Sanford、Maine、美国、04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough、Maine、美国、04074
- Maine Children's Cancer Program
-
Scarborough、Maine、美国、04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland、Maine、美国、04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
South Portland、Maine、美国、04106
- MaineHealth Urology - South Portland
-
-
Michigan
-
Ann Arbor、Michigan、美国、48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton、Michigan、美国、48114
- Trinity Health Medical Center - Brighton
-
Canton、Michigan、美国、48188
- Trinity Health Medical Center - Canton
-
Chelsea、Michigan、美国、48118
- Chelsea Hospital
-
Grand Rapids、Michigan、美国、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Iron Mountain、Michigan、美国、49801
- Dickinson County Healthcare System
-
Livonia、Michigan、美国、48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac、Michigan、美国、48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
-
Missouri
-
Ballwin、Missouri、美国、63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Joplin、Missouri、美国、64804
- Freeman Health System
-
Joplin、Missouri、美国、64804
- Mercy Hospital Joplin
-
Rolla、Missouri、美国、65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla、Missouri、美国、65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph、Missouri、美国、64506
- Heartland Regional Medical Center
-
Springfield、Missouri、美国、65807
- CoxHealth South Hospital
-
Springfield、Missouri、美国、65804
- Mercy Hospital Springfield
-
St Louis、Missouri、美国、63131
- Missouri Baptist Medical Center
-
St Louis、Missouri、美国、63109
- Mercy Infusion Center - Chippewa
-
St Louis、Missouri、美国、63141
- Mercy Hospital Saint Louis
-
St Louis、Missouri、美国、63128
- Mercy Hospital South
-
Washington、Missouri、美国、63090
- Mercy Hospital Washington
-
-
Montana
-
Billings、Montana、美国、59102
- Saint Vincent Frontier Cancer Center
-
Butte、Montana、美国、59701
- Saint James Community Hospital and Cancer Treatment Center
-
-
Nebraska
-
Grand Island、Nebraska、美国、68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
-
Nevada
-
Carson City、Nevada、美国、89703
- Carson Tahoe Regional Medical Center
-
Las Vegas、Nevada、美国、89102
- OptumCare Cancer Care at Charleston
-
Las Vegas、Nevada、美国、89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas、Nevada、美国、89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas、Nevada、美国、89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas、Nevada、美国、89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas、Nevada、美国、89103
- Hope Cancer Care of Nevada
-
Las Vegas、Nevada、美国、89183
- OptumCare Cancer Care at Fort Apache
-
-
New Hampshire
-
Nashua、New Hampshire、美国、03060
- Saint Joseph Hospital
-
-
New Jersey
-
Morristown、New Jersey、美国、07960
- Morristown Medical Center
-
Newton、New Jersey、美国、07860
- Newton Medical Center
-
Pompton、New Jersey、美国、07444
- Chilton Medical Center
-
Summit、New Jersey、美国、07902
- Overlook Hospital
-
-
New York
-
New York、New York、美国、10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
The Bronx、New York、美国、10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx、New York、美国、10467
- Children's Hospital at Montefiore
-
The Bronx、New York、美国、10467
- Montefiore Medical Center - Moses Campus
-
The Bronx、New York、美国、10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- Novant Health Presbyterian Medical Center
-
Greenville、North Carolina、美国、27834
- East Carolina University
-
Greenville、North Carolina、美国、27834
- ECU Health Medical Center
-
Kernersville、North Carolina、美国、27284
- Novant Health Cancer Institute - Kernersville
-
Kinston、North Carolina、美国、28501
- ECU Health Oncology Kinston
-
Mount Airy、North Carolina、美国、27030
- Novant Health Cancer Institute - Mount Airy
-
Pinehurst、North Carolina、美国、28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Thomasville、North Carolina、美国、27360
- Novant Health Cancer Institute - Thomasville
-
Washington、North Carolina、美国、27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
Winston-Salem、North Carolina、美国、27103
- Novant Health Forsyth Medical Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73120
- Mercy Hospital Oklahoma City
-
-
Rhode Island
-
Providence、Rhode Island、美国、02908
- Roger Williams Medical Center
-
-
South Carolina
-
Columbia、South Carolina、美国、29203
- Prisma Health Richland Hospital
-
Columbia、South Carolina、美国、29220
- Prisma Health Baptist Hospital
-
Gaffney、South Carolina、美国、29341
- Gibbs Cancer Center-Gaffney
-
Greenville、South Carolina、美国、29605
- Prisma Health Greenville Memorial Hospital
-
Greer、South Carolina、美国、29651
- Gibbs Cancer Center-Pelham
-
Spartanburg、South Carolina、美国、29303
- Spartanburg Medical Center
-
Union、South Carolina、美国、29379
- SMC Center for Hematology Oncology Union
-
-
Texas
-
San Antonio、Texas、美国、78229
- Audie L Murphy VA Hospital
-
-
Virginia
-
Lynchburg、Virginia、美国、24501
- Centra Alan B Pearson Regional Cancer Center
-
Richmond、Virginia、美国、23235
- VCU Massey Cancer Center at Stony Point
-
Richmond、Virginia、美国、23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Renton、Washington、美国、98055
- Valley Medical Center
-
Yakima、Washington、美国、98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Huntington、West Virginia、美国、25701
- Edwards Comprehensive Cancer Center
-
Morgantown、West Virginia、美国、26505
- Monongalia Hospital
-
-
Wisconsin
-
Eau Claire、Wisconsin、美国、54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield、Wisconsin、美国、54449
- Marshfield Medical Center-Marshfield
-
Milwaukee、Wisconsin、美国、53215
- Aurora Saint Luke's Medical Center
-
Minocqua、Wisconsin、美国、54548
- Marshfield Medical Center - Minocqua
-
Rice Lake、Wisconsin、美国、54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point、Wisconsin、美国、54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston、Wisconsin、美国、54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids、Wisconsin、美国、54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients undergoing treatment for cancer types with commercially available therapies.
描述
Inclusion Criteria:
-
Is consistent with OR has been diagnosed with one of the following:
-
Colorectal cancer: stage IV
-
Non-small cell or small cell lung cancer: stage III/IV
-
Prostate cancer: metastatic prostate cancer
-
Gastric cancer, not otherwise specified (NOS): stage IV
-
Esophageal cancer, NOS: stage IV
-
Adenocarcinoma of gastroesophageal junction: stage IV
-
High grade serous ovarian cancer: stage III/IV
-
Invasive breast carcinoma: stage III/IV
-
Melanoma: stage III/IV
-
Acute myeloid leukemia
-
Multiple myeloma
-
For the purposes of this study,
- Re-staging is allowed
- Having more than one primary cancer is allowed, if the patient is being treated solely for one of the eligible cancers listed above
-
-
-
Patient should fit in one of the following four clinical scenarios (a-d)
- Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
- Scheduled to begin treatment with a new regimen of standard of care therapy OR
- Currently progressing on a regimen of standard of care therapy OR
- Currently being treated with a regimen standard of care therapy, without evidence of progression
-
Requirements for fresh tissue biospecimen collections at enrollment:
-
For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment
-
For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy
-
For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure
-
For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR
-
The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling
- Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
-
-
-
Requirements for archival tissue:
-
For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE
-
For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED
-
Pre-existing archival material (formalin-fixed, paraffin-embedded [FFPE] block, BM aspirate, or unstained slides) that:
- Contains the cancer type for which the participant is enrolled, and
- Was collected no more than 5 years prior to initiation of therapy, and
- Contains at least a surface area of 5 mm^2 and optimal surface area of 25 mm^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
- Contains at least 10% tumor content. 70% tumor content is optimal, and
- No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
-
-
Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment
- Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
- Blood collection for clinical scenario d must take place within 4 weeks of enrollment, and while patient is on treatment
-
Age 13 or older
-
Any sex
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
-
Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC who are 40 years old or younger at time of collection irrespective of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with BRCA that are either
- Any race/ethnicity with hormone receptor positive (ER+PR+, ER+PR-, or ER-PR+)
- African American with triple negative (ER-PR-HER2-)
-
NCI PDMR INCLUSION CRITERIA: Patients with lung cancer (LCA), prostate cancer (PCA), gastroesophageal cancer (GEC), ovarian cancer (OV), acute myeloid leukemia (AML), multiple myeloma (MML)
Exclusion Criteria:
-
Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial
- For the purposes of this study, past enrollment in clinical trials whereby the patient was randomized and treated with standard-of-care anti-cancer treatment (chemotherapy regimen, surgery and radiation therapy) is allowed
-
Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy
-
Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion
-
Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use
-
Factor X inhibitors are permitted
-
Use of anti-platelet drugs are permitted
- Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
-
-
NCI PDMR EXCLUSION CRITERIA: Patients with complete response
-
NCI PDMR EXCLUSION CRITERIA: Patients with invasive fungal infections
-
NCI PDMR EXCLUSION CRITERIA: Patients with active and/or uncontrolled infections or who are still recovering from an infection
- Actively febrile patients with uncertain etiology of febrile episode
- All antibiotics for non-prophylactic treatment of infection should be completed at least 1 week (7 days) prior to collection
- No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
-
NCI PDMR EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e. quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HBV/HCV without documented resolution
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Observational (biospecimen collection, chart review)
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo CT, PET/CT and/or MRI throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years. |
Undergo CT
其他名称:
Undergo MRI
其他名称:
Undergo PET/CT
其他名称:
Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
其他名称:
Medical charts are reviewed and data is collected
其他名称:
Undergo paracentesis |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Procure, store and distribute longitudinal biospecimens and associated clinical data
大体时间:Up to 10 years
|
Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study aggregate. |
Up to 10 years
|
|
Percentage of enrolled patients by cancer type and treatment regimen overall
大体时间:Until completion of biospecimen collection, up to 3 years
|
Will assess the percentage of enrolled patients by cancer type and treatment regimen overall and those who contribute samples to the Drug Resistance and Sensitivity Network and other approved investigators. Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of minority and underserved study participants accrued
大体时间:Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of minority and underserved study participants accrued
大体时间:Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Pan-cancer gene panel tumor next generation sequencing test
大体时间:Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
大体时间:Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling is attempted
大体时间:Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling results are generated
大体时间:Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom samples are obtained at each longitudinal timepoint
大体时间:Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
大体时间:Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
合作者和调查者
调查人员
- 首席研究员:Lyndsay N Harris、National Cancer Institute (NCI)
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 内分泌系统疾病
- 血管疾病
- 心血管疾病
- 生殖器肿瘤,男性
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 生殖器疾病,男性
- 前列腺疾病
- 男性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 肠道疾病
- 免疫系统疾病
- 呼吸道疾病
- 组织学类型的肿瘤
- 消化道肿瘤
- 消化系统肿瘤
- 消化系统疾病
- 肠胃疾病
- 胃病
- 肠道肿瘤
- 直肠疾病
- 生殖器疾病,女性
- 肺部疾病
- 血液病
- 内分泌腺肿瘤
- 头颈肿瘤
- 呼吸道肿瘤
- 胸部肿瘤
- 结肠疾病
- 食道疾病
- 卵巢疾病
- 附件疾病
- 生殖器肿瘤,女性
- 性腺疾病
- 皮肤病
- 乳腺疾病
- 淋巴增生性疾病
- 免疫增生性疾病
- 神经外胚层肿瘤
- 肿瘤、生殖细胞和胚胎
- 肿瘤,神经组织
- 白血病,骨髓
- 癌,支气管癌
- 支气管肿瘤
- 神经内分泌肿瘤
- 肿瘤,浆细胞
- 止血障碍
- 副蛋白血症
- 血液蛋白失调
- 出血性疾病
- 白血病
- 痣和黑色素瘤
- 皮肤肿瘤
- 输卵管疾病
- 乳腺肿瘤
- 皮肤和结缔组织疾病
- 半身和淋巴疾病
- 前列腺肿瘤
- 胃肿瘤
- 肺肿瘤
- 结直肠肿瘤
- 白血病,骨髓,急性
- 食道肿瘤
- 卵巢肿瘤
- 癌,非小细胞肺癌
- 多发性骨髓瘤
- 小细胞肺癌
- 黑色素瘤
- 三阴性乳腺肿瘤
- 输卵管肿瘤
- 调查技术
- 疗法
- 临床实验室技术
- 诊断技术和程序
- 诊断
- 穿刺
- 手术程序,手术
- 化学技术,分析
- 频谱分析
- 引流
- 标本处理
- 磁共振光谱
- 可穿梭化
其他研究编号
- NCI-2020-00750
- NCI-2020-00750 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- 10323 (其他标识符:CTEP)
- 10323 (其他标识符:Division of Cancer Treatment and Diagnosis)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.